Understanding immune responses in atopic dermatitis patients treated with dupilumab
Pattern Recognition of Immune Cells in Atopic Dermatitis Patients Receiving Dupilumab
This study is testing how dupilumab treatment changes immune cells in people with atopic dermatitis to see if it can help doctors create more personalized treatment plans.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 25 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Charite University, Berlin, Germany Academic / other |
| Drugs / interventions | dupilumab |
| Locations | 1 site (Berlin) |
| Trial ID | NCT05098821 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the changes in immune cell compositions in patients with atopic dermatitis who are undergoing treatment with dupilumab. By utilizing a novel pattern recognition of immune cells (PRI) approach, the study seeks to identify different phenotypes of treatment responders and non-responders. Blood samples will be collected at various intervals to analyze T cell subpopulations and their responses to the treatment. The findings could lead to more personalized therapeutic strategies for managing atopic dermatitis.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and above with a diagnosis of atopic dermatitis for at least one year and who have not responded adequately to topical treatments.
Not a fit: Patients under 18 years old or those with known allergies to dupilumab or other conditions that could interfere with the assessment of atopic dermatitis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enable more personalized treatment approaches for patients with atopic dermatitis, improving outcomes for those who do not respond to standard therapies.
How similar studies have performed: While the PRI approach is relatively novel, similar studies exploring immune responses in atopic dermatitis have shown promising results in identifying treatment responders.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 and above * Diagnosis of atopic dermatitis for ≥1 year * Inadequate response to treatment with topical medications * Confirmed dupilumab treatment Exclusion Criteria: * Age below 18 * Known or suspected allergy or reaction to any component of the dupilumab formulation * Known active allergic or irritant contact dermatitis that is likely to interfere with the assessment of the severity of AD * Severe conjunctivitis or blepharitis
Where this trial is running
Berlin
- Dpt of Dermatology and Allergology, Charité - Universitätsmedizin Berlin — Berlin, Germany (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.